LAMEA Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Country, Industry Analysis and Forecast, 2020 - 2026
The Latin America, Middle East and Africa Neutropenia Treatment Market would witness market growth of 7.4% CAGR during the forecast period (2020-2026).
Neutropenia is a disease in which the number of white blood cells (neutrophils) in the bloodstream is reduced, decreasing the body 's capacity to combat infections. Neutropenia is classified as an absolute neutrophil count (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL.
The neutropenia market is expected to grow significantly in the future due to an increase in the incidence of cancer cases. In addition, a surge in R&D activities by companies to improve novel neutropenia treatment is projected to fuel demand growth throughout the forecast period. Nonetheless, the high cost of neutropenia treatment and the stringent rules and regulations for product approvals are likely to impede the growth of the market for neutropenia treatment during the forecast period. On the contrary, the transition from branded drugs to low-cost biosimilars is expected to provide market players with remunerative opportunities.
One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals with immune-boosting effects, is expected to revolutionize the therapeutic regimen for neutropenia. In addition to the immune-boosting effects, the Phase II studies have revealed much more beneficial anti-cancer effects of this molecule.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
Neutropenia is a disease in which the number of white blood cells (neutrophils) in the bloodstream is reduced, decreasing the body 's capacity to combat infections. Neutropenia is classified as an absolute neutrophil count (ANC) below 1500 per microliter (1500/microL); severe neutropenia is defined as an ANC below 500/microL.
The neutropenia market is expected to grow significantly in the future due to an increase in the incidence of cancer cases. In addition, a surge in R&D activities by companies to improve novel neutropenia treatment is projected to fuel demand growth throughout the forecast period. Nonetheless, the high cost of neutropenia treatment and the stringent rules and regulations for product approvals are likely to impede the growth of the market for neutropenia treatment during the forecast period. On the contrary, the transition from branded drugs to low-cost biosimilars is expected to provide market players with remunerative opportunities.
One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals with immune-boosting effects, is expected to revolutionize the therapeutic regimen for neutropenia. In addition to the immune-boosting effects, the Phase II studies have revealed much more beneficial anti-cancer effects of this molecule.
Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.
Scope of the Study
Market Segmentation:
By Distribution Channel
- Retail pharmacies
- Hospital pharmacies and
- Online pharmacies
- Colony-stimulating factor
- Antibiotics
- Antifungals and
- Antivirals
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
- Amgen, Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- BeyondSpring, Inc.
- Spectrum Pharmaceuticals, Inc.
- Kyowa Kirin Co., Ltd. (Kirin Company)
- Mylan N.V.
- Cellerant Therapeutics, Inc.
- Partner Therapeutics, Inc.
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Neutropenia Treatment Market, by Distribution Channel
1.4.2 LAMEA Neutropenia Treatment Market, by Treatment
1.4.3 LAMEA Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 LAMEA Retail pharmacies Market by Country
3.2 LAMEA Hospital pharmacies Market by Country
3.3 LAMEA Online pharmacies Market by Country
CHAPTER 4. LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 LAMEA Colony-stimulating factor Market by Country
4.2 LAMEA Antibiotics Market by Country
4.3 LAMEA Antifungals Market by Country
4.4 LAMEA Antivirals Market by Country
CHAPTER 5. LAMEA NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 Brazil Neutropenia Treatment Market
5.1.1 Brazil Neutropenia Treatment Market by Distribution channel
5.1.2 Brazil Neutropenia Treatment Market by Treatment
5.2 Argentina Neutropenia Treatment Market
5.2.1 Argentina Neutropenia Treatment Market by Distribution channel
5.2.2 Argentina Neutropenia Treatment Market by Treatment
5.3 UAE Neutropenia Treatment Market
5.3.1 UAE Neutropenia Treatment Market by Distribution channel
5.3.2 UAE Neutropenia Treatment Market by Treatment
5.4 Saudi Arabia Neutropenia Treatment Market
5.4.1 Saudi Arabia Neutropenia Treatment Market by Distribution channel
5.4.2 Saudi Arabia Neutropenia Treatment Market by Treatment
5.5 South Africa Neutropenia Treatment Market
5.5.1 South Africa Neutropenia Treatment Market by Distribution channel
5.5.2 South Africa Neutropenia Treatment Market by Treatment
5.6 Nigeria Neutropenia Treatment Market
5.6.1 Nigeria Neutropenia Treatment Market by Distribution channel
5.6.2 Nigeria Neutropenia Treatment Market by Treatment
5.7 Rest of LAMEA Neutropenia Treatment Market
5.7.1 Rest of LAMEA Neutropenia Treatment Market by Distribution channel
5.7.2 Rest of LAMEA Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Neutropenia Treatment Market, by Distribution Channel
1.4.2 LAMEA Neutropenia Treatment Market, by Treatment
1.4.3 LAMEA Neutropenia Treatment Market, by Country
1.5 Methodology for the research
CHAPTER 2. MARKET OVERVIEW
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
CHAPTER 3. LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL
3.1 LAMEA Retail pharmacies Market by Country
3.2 LAMEA Hospital pharmacies Market by Country
3.3 LAMEA Online pharmacies Market by Country
CHAPTER 4. LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT
4.1 LAMEA Colony-stimulating factor Market by Country
4.2 LAMEA Antibiotics Market by Country
4.3 LAMEA Antifungals Market by Country
4.4 LAMEA Antivirals Market by Country
CHAPTER 5. LAMEA NEUTROPENIA TREATMENT MARKET BY COUNTRY
5.1 Brazil Neutropenia Treatment Market
5.1.1 Brazil Neutropenia Treatment Market by Distribution channel
5.1.2 Brazil Neutropenia Treatment Market by Treatment
5.2 Argentina Neutropenia Treatment Market
5.2.1 Argentina Neutropenia Treatment Market by Distribution channel
5.2.2 Argentina Neutropenia Treatment Market by Treatment
5.3 UAE Neutropenia Treatment Market
5.3.1 UAE Neutropenia Treatment Market by Distribution channel
5.3.2 UAE Neutropenia Treatment Market by Treatment
5.4 Saudi Arabia Neutropenia Treatment Market
5.4.1 Saudi Arabia Neutropenia Treatment Market by Distribution channel
5.4.2 Saudi Arabia Neutropenia Treatment Market by Treatment
5.5 South Africa Neutropenia Treatment Market
5.5.1 South Africa Neutropenia Treatment Market by Distribution channel
5.5.2 South Africa Neutropenia Treatment Market by Treatment
5.6 Nigeria Neutropenia Treatment Market
5.6.1 Nigeria Neutropenia Treatment Market by Distribution channel
5.6.2 Nigeria Neutropenia Treatment Market by Treatment
5.7 Rest of LAMEA Neutropenia Treatment Market
5.7.1 Rest of LAMEA Neutropenia Treatment Market by Distribution channel
5.7.2 Rest of LAMEA Neutropenia Treatment Market by Treatment
CHAPTER 6. COMPANY PROFILES
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:
LIST OF TABLES
TABLE 1 LAMEA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 LAMEA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 LAMEA RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 LAMEA RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 LAMEA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 LAMEA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 LAMEA ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 LAMEA ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 LAMEA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 LAMEA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 LAMEA ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 LAMEA ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 LAMEA ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 LAMEA ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 LAMEA ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 LAMEA ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 LAMEA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 LAMEA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 BRAZIL NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 BRAZIL NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 BRAZIL NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 BRAZIL NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 BRAZIL NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 BRAZIL NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 ARGENTINA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 ARGENTINA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 ARGENTINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 ARGENTINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 ARGENTINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 ARGENTINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 UAE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 UAE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 UAE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 UAE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 UAE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 40 UAE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 48 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 49 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 50 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 51 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 52 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 53 NIGERIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 54 NIGERIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 55 NIGERIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 56 NIGERIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 57 NIGERIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 58 NIGERIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 59 REST OF LAMEA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 60 REST OF LAMEA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 61 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 62 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 63 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 64 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 65 KEY INFORMATION – AMGEN, INC.
TABLE 66 KEY INFORMATION – NOVARTIS AG
TABLE 67 KEY INFORMATION – PFIZER, INC.
TABLE 68 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 69 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 70 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 71 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 72 KEY INFORMATION – MYLAN N.V.
TABLE 73 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 74 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
TABLE 1 LAMEA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 2 LAMEA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 3 LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 4 LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 5 LAMEA RETAIL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 6 LAMEA RETAIL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 7 LAMEA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 8 LAMEA HOSPITAL PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 9 LAMEA ONLINE PHARMACIES MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 10 LAMEA ONLINE PHARMACIES MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 11 LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 12 LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 13 LAMEA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 14 LAMEA COLONY-STIMULATING FACTOR MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 15 LAMEA ANTIBIOTICS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 16 LAMEA ANTIBIOTICS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 17 LAMEA ANTIFUNGALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 18 LAMEA ANTIFUNGALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 19 LAMEA ANTIVIRALS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 20 LAMEA ANTIVIRALS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 21 LAMEA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 22 LAMEA NEUTROPENIA TREATMENT MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 23 BRAZIL NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 24 BRAZIL NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 25 BRAZIL NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 26 BRAZIL NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 27 BRAZIL NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 28 BRAZIL NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 29 ARGENTINA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 30 ARGENTINA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 31 ARGENTINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 32 ARGENTINA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 33 ARGENTINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 34 ARGENTINA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 35 UAE NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 36 UAE NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 37 UAE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 38 UAE NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 39 UAE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 40 UAE NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 41 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 42 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 43 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 44 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 45 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 46 SAUDI ARABIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 47 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 48 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 49 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 50 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 51 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 52 SOUTH AFRICA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 53 NIGERIA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 54 NIGERIA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 55 NIGERIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 56 NIGERIA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 57 NIGERIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 58 NIGERIA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 59 REST OF LAMEA NEUTROPENIA TREATMENT MARKET, 2016 - 2019, USD MILLION
TABLE 60 REST OF LAMEA NEUTROPENIA TREATMENT MARKET, 2020 - 2026, USD MILLION
TABLE 61 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2016 - 2019, USD MILLION
TABLE 62 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY DISTRIBUTION CHANNEL, 2020 - 2026, USD MILLION
TABLE 63 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2016 - 2019, USD MILLION
TABLE 64 REST OF LAMEA NEUTROPENIA TREATMENT MARKET BY TREATMENT, 2020 - 2026, USD MILLION
TABLE 65 KEY INFORMATION – AMGEN, INC.
TABLE 66 KEY INFORMATION – NOVARTIS AG
TABLE 67 KEY INFORMATION – PFIZER, INC.
TABLE 68 KEY INFORMATION – TEVA PHARMACEUTICALS INDUSTRIES LTD.
TABLE 69 KEY INFORMATION – BEYONDSPRING, INC.
TABLE 70 KEY INFORMATION – SPECTRUM PHARMACEUTICALS, INC.
TABLE 71 KEY INFORMATION – KYOWA KIRIN CO., LTD.
TABLE 72 KEY INFORMATION – MYLAN N.V.
TABLE 73 KEY INFORMATION – CELLERANT THERAPEUTICS, INC.
TABLE 74 KEY INFORMATION – PARTNER THERAPEUTICS, INC.
LIST OF FIGURES
FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 1 METHODOLOGY FOR THE RESEARCH
